

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION  
(Translated from Hebrew)

Assets	December	
	2019	2018
	NIS in thousands	
<b>CURRENT ASSETS:</b>		
Cash and cash equivalents	28,392	5,901
Receivables:		
Trade receivables	3,925	1,345
Other receivables	1,934	540
Current tax assets	363	-
Inventory	12,195	10,260
Biological assets	1,957	2,895
	<u>48,766</u>	<u>20,941</u>
<b>NON-CURRENT ASSETS:</b>		
Property, plant and equipment	8,699	6,175
Operating lease right of use assets	1,932	-
Investments in associates	1,474	896
Financial assets	6,257	5,501
	<u>18,362</u>	<u>12,572</u>
<b>TOTAL ASSETS</b>	<b><u>67,128</u></b>	<b><u>33,513</u></b>
<b>Liabilities and equity</b>		
<b>CURRENT LIABILITIES -</b>		
Accounts payable:		
Trade payables	876	480
Other payables	1,492	920
Deferred and contingent liabilities	13,533	-
Current tax liability	-	472
Loans from shareholders	-	5,951
	<u>15,901</u>	<u>7,823</u>
<b>NON-CURRENT LIABILITIES:</b>		
Deferred tax liability	2,571	3,880
Operating lease liabilities	1,782	-
Retirement benefits liabilities, net	113	90
	<u>4,466</u>	<u>3,970</u>
<b>EQUITY:</b>		
Share capital and share premium	49,430	10
Other equity reserves	1,241	3,066
Accumulated earnings (loss)	(3,910)	18,644
	<u>46,761</u>	<u>21,720</u>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b><u>67,128</u></b>	<b><u>33,513</u></b>

# Seach\*

MEDICAL GROUP

## CONSOLIDATED INCOME STATEMENTS

(Translated from Hebrew)

Year ended December 31

	2019	2018	2017
	NIS in thousands		
Revenue from sales	28,834	18,549	12,302
Cost of sales	14,970	9,369	7,012
<b>GROSS PROFIT BEFORE FAIR VALUE ADJUSTMENTS</b>	<b>13,864</b>	<b>9,180</b>	<b>5,290</b>
Unrealized gain on changes in fair value of biological assets	7,962	7,045	3,805
Fair value changes in biological assets sold	(8,082)	(3,622)	(3,725)
<b>GROSS PROFIT AFTER FAIR VALUE ADJUSTMENTS</b>	<b>13,744</b>	<b>12,603</b>	<b>5,370</b>
Research and development expenses	1,806	456	493
Sales and marketing expenses	2,078	1,436	776
General and administrative expenses	5,238	1,730	902
Listing cost of reverse acquisition	28,765	-	-
Loss from disposal and decrease in holding stake in associates	783	338	1
Other income	(876)	(410)	(632)
<b>OPERATING INCOME (LOSS)</b>	<b>(24,050)</b>	<b>9,053</b>	<b>3,830</b>
Finance expenses	468	156	115
Finance income	3,531	1,470	7
Financial income (expenses), net	3,063	1,314	(108)
<b>INCOME (LOSS) BEFORE TAXES</b>	<b>(20,987)</b>	<b>10,367</b>	<b>3,722</b>
Tax expenses	1,567	2,352	765
<b>NET INCOME (LOSS)</b>	<b>(22,554)</b>	<b>8,015</b>	<b>2,957</b>
<b>OTHER COMPREHENSIVE INCOME (LOSS)</b>			
<b>Items that will be reclassified into profit or loss -</b>			
Translation differences, net	(1)	-	-
<b>Items that will not be reclassified into profit or loss -</b>			
Profit (loss) from financial assets at fair value, net of tax	(1,518)	(11,718)	8,268
<b>TOTAL OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX</b>	<b>(1,519)</b>	<b>(11,718)</b>	<b>8,268</b>
<b>TOTAL COMPREHENSIVE PROFIT (LOSS)</b>	<b>(24,073)</b>	<b>(3,703)</b>	<b>11,225</b>
<b>PROFIT (LOSS) PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY:</b>			
Basic and diluted	(0.08)	0.03	0.01